All News
Filter News
Found 808,479 articles
-
Evofem Biosciences Announces Publication in Peer-Reviewed Journal Advances in Therapy
9/27/2021
Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that a manuscript on the variability of contraceptive clinical trial design and its impact on efficacy outcomes has been published in the peer-reviewed journal Advances in Therapy.
-
Dr. Ernst Von Schwarz: Study Shows Promising Benefit of Mesenchymal Stem Cell Injection in Critically Ill COVID-19 Patients
9/27/2021
COVID-19 infections represent a life-threatening condition secondary to respiratory and multi-organ failure as a result of a systemic inflammatory response. Stem cell therapy might ameliorate the underlying effects likely secondary to anti-inflammatory properties.
-
Inotiv, Inc. Announces Closing of $125 Million Convertible Senior Notes Offering and Full Exercise of Option to Purchase Additional $15 Million of Notes
9/27/2021
The gross proceeds to the Company were approximately $134.5 million after deducting the initial purchaser’s discounts and commissions and estimated offering expenses.
-
Fierce Biotech Names Tectonic Therapeutic as One of Its “Fierce 15” Biotech Companies of 2021
9/27/2021
Tectonic Therapeutic today announced that Fierce Biotech has named it as one of 2021’s Fierce 15 biotechnology companies, designating it as one of the most promising early-stage biotechnology companies in the industry.
-
Altimmune to Announce 12-Week Data From ALT-801 Phase 1 Trial on September 28, 2021
9/27/2021
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report the results from its 12-week Phase 1 clinical trial of ALT-801 in overweight and obese subjects in a pre-market press release and webcast to be held on Tuesday, September 28, 2021.
-
RegeneRx Licensee Acquired by Korean Biopharmaceutical Group
9/27/2021
RegeneRx Biopharmaceuticals, Inc. today announced that GtreeBNT, the licensee for several RegeneRx products, is being acquired by HLB Group, a Korean company
-
Mosaic ImmunoEngineering Announces Keynote Presentation Highlighting its Modular Vaccine Platform Delivery Technology
9/27/2021
- Presentation highlighted potential of polymer-based delivery system for slow-release of vaccines that potentially require no booster shots
-
CGBIO to introduce AI-empowered robotic intervention device, with clinical trials
9/27/2021
CGBIO, NDR Medical Technology, forge a partnership in a move to introduce puncture robot technology and collaborate in clinical studies.
-
Acasti Pharma Announces Initiation of Pharmacokinetic Bridging Study for GTX-104, the Company’s Lead Drug Candidate for the Treatment of Subarachnoid Hemorrhage
9/27/2021
Acasti Pharma Inc. today announces the initiation of its planned pharmacokinetic (PK) bridging study to evaluate the relative bioavailability of intravenous (IV) GTX-104 compared to currently marketed oral nimodipine capsules in 50 healthy subjects.
-
Aditxt Appoints Corinne Pankovcin as President and Thomas J. Farley as Chief Financial Officer as Company Prepares for Global Commercialization
9/27/2021
Aditxt, Inc. today announced key executive management changes to support its growth plans. Corinne Pankovcin, who has served as CFO of Aditxt, has been appointed as President and will work closely with the Company’s CEO, Amro Albanna, to execute Aditxt’s business strategy.
-
Denali Therapeutics Appoints Katie Peng as Chief Commercial Officer
9/27/2021
Denali Therapeutics Inc. today announced the appointment of Katie Peng to the newly created role of Chief Commercial Officer.
-
Ribon Therapeutics Named a “Fierce 15” Biotech Company by Fierce Biotech
9/27/2021
Ribon Therapeutics today announced it has been named by Fierce Biotech as one of 2021’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry.
-
Sarepta Therapeutics to Initiate Part B of MOMENTUM Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping Following Positive Interactions with FDA
9/27/2021
Sarepta Therapeutics, Inc. today announced that following positive interactions with the U.S. Food and Drug Administration (FDA), the Company plans to initiate Part B of the MOMENTUM study (Study 5051-201), in the fourth quarter.
-
Boehringer Ingelheim and Invetx Announce Strategic Collaboration to Advance Monoclonal Antibody Biotherapeutics in Animal Health
9/27/2021
Boehringer Ingelheim and Invetx are pleased to announce they have entered into a collaboration agreement to develop novel, species-specific monoclonal antibody (mAb) biotherapeutics targeting a wide range of diseases in the veterinary species, initially focused on dogs and cats.
-
Precision BioSciences Announces Grant of Inducement Award for Newly Appointed Chief Executive Officer Pursuant to Nasdaq Listing Rule 5635(c)(4)
9/27/2021
Precision BioSciences, Inc. today announced an inducement grant for Michael Amoroso, newly appointed President and Chief Executive Officer of Precision BioSciences.
-
Semler Scientific to Commence Trading on Nasdaq
9/27/2021
Semler Scientific, Inc. today announced that The Nasdaq Stock Market LLC ("Nasdaq") has approved the listing of its ommon stock on the exchange. Semler Scientific's common stock will begin trading on The Nasdaq Capital Market under the trading symbol "SMLR" at the open of the market on Tuesday, September 28, 2021.
-
Syros Announces Appointment of Conley Chee as Chief Commercial Officer
9/27/2021
Syros Pharmaceuticals today announced the appointment of Conley Chee as the company’s first Chief Commercial Officer.
-
Apnimed Expands Executive Leadership Team Appointing Rob Rode Chief Commercial Officer
9/27/2021
Apnimed today announced that Rob Rode has joined the company as Chief Commercial Officer.
-
Bio-Thera Solutions and Intract Pharma Enter Global Collaboration and License Agreement for Soteria® and Phloral® Drug Delivery Technologies to Enable Development of Oral Antibody Medicines
9/27/2021
Bio-Thera Solutions, Ltd. (688177.SH, “Bio-Thera”) and Intract Pharma (“Intract”) announced a global collaboration and licensing agreement that gives Bio-Thera access to Intract’s Soteria® and Phloral® drug delivery technologies to develop novel oral monoclonal antibody (mAb) treatments for chronic gastrointestinal (GI) inflammatory diseases.
-
KSL Biomedical, Inc. Announces Expansion to Canada with Acquisition of Pulse Scientific
9/27/2021
KSL Biomedical, Inc. announces expansion into Canada with the acquisition of Pulse Scientific, Inc.